VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the 4th Annual Immuno-Oncology Summit on Wednesday, August 31, 2016 at 11:15 AM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA.
During the presentation, eVLP Delivery of Novel Foreign Antigens Elicits Polyvalent Anti-Tumor Immunity, Adam Buckley, VBI’s Vice President of Business Development, will summarize recent progress in the company’s glioblastoma multiforme (“GBM”) and medulloblastoma (“MB”) immunotherapy programs, including new data that demonstrates VBI-1901’s ability to stimulate dendritic cell responses.
VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. VBI has applied its eVLP Platform in the development of VBI-1901, a multivalent therapeutic vaccine candidate designed to direct an immune response against cytomegalovirus (“CMV”) viral antigens that are frequently expressed in certain cancers, including GBM1, MB2, and breast3. In preclinical studies, VBI-1901 stimulated immune responses critical to efficacious anti-tumor immunity, including CD4+ and CD8+ T cell responses in GBM patient samples.
New preclinical data demonstrates VBI-1901’s ability to recruit and activate dendritic cells, as evidenced by induction of proinflammatory IL-8 cytokine and CCL3 chemokine responses in an ex vivo model. Dendritic cells are critical to antigen presentation and the initiation of an adaptive immune response.
“VBI-1901 has the potential to be an off-the-shelf immunotherapy that activates both T cells and dendritic cells,” said Mr. Buckley. “Leveraging tumor associated viral antigens, in this case CMV, allows VBI-1901 to harness the immune system’s vigorous antiviral response to directly target CMV-infected tumors.”
- Event: 4th Annual Immuno-Oncology Summit
- Date: Wednesday, August 31, 2016
- Time: 11:15 AM ET
- Location: Marriott Long Wharf Hotel in Boston, MA
- Event Website: http://www.immuno-
- Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncology. 2008;10(1):10-8.
- David Weild IV. Baryawno N, Rahbar A, Wolmer-solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121(10):4043-55.
- Taher C, De boniface J, Mohammad AA, et al. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS ONE. 2013;8(2):e56795.
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements. Such forward-looking statements included, but are not limited to: VBI-1901’s efficacy in VBI’s immunotherapy programs.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.